Intra-peritoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma

Figures & data

Table I.  Patient characteristics.

Characteristic	Number of patients (%)
Stage
III	37/41 (90%)
IV	4/41 (10%)
Initial cytoreductive surgery
Optimal	17/41 (42%)
Sub-optimal	18/41 (44%)
Unknown	6/41 (14%)
First-line chemotherapy
Cisplatin/cyclophosphamide	13/41 (32%)
Cisplatin/paclitaxel	11/41 (27%)
Carboplatin/paclitaxel	10/41 (24%)
Cisplatin/cyclophosphamide/adriamycin	2/41 (5%)
Paclitaxel/cisplatin/carboplatin	2/41 (5%)
Paclitaxel	1/41 (2%)
Melphalan	1/41 (2%)
No therapy	1/41 (2%)
Platinum-free interval
≤6 months	37/41 (90%)
>6 months	4/41 (10%)

Table II.  Treatment toxicity by CDDP dose.

CDDP dose (mg m^−2)	Renal toxicity events/#patients	Allergic reaction events/#patients	Catheter complications events/#patients	Hyperthermia complications events/#patients
60	0/3	1/3	0/3	0/3
100	0/9	2/9	1/9 (peritonitis)	2/9
				2nd degree burns
140	0/9	2/9	3/9 (obstruction)	0/9
180	3/20	1/20	5/20	0/20
			3 obstruction
			2 infection

Table III.  Thermal data on individual patients.

CDDP=	HT#1 Max tumour temp	HT#1 Max normal temp	HT#2 Max tumour temp	HT#2 Max normal temp	HT#3 Max tumour temp	HT#3 Max normal temp	HT#4 Max tumour temp	HT#4 Max normal temp	HT#5 Max tumour temp	HT#5 Max normal temp	HT#6 Max tumour temp	HT#6 Max normal temp
60	42.1	41.9	40.9	41.3	41.8	40.9	42.4	43.2	41.1	40.5	41.6	41.7
60	41.7	40.9	42.3	41.7	42.1	43.0	44.6	42.2	42.3	41.6	42.2	41.8
60	42.2	40.4	41.8	41.0	41.2	41.0	40.9	41.6	41.5	41.3	42.2	41.2
100	42.9	41.3	41.9	40.4	42.0	41.4	42.7	41.6	41.1	41.5	39.9	41.4
100	41.6	41.7	41.9	41.0	41.9	41.1	41.5	41.9	41.4	41.0	41.6	40.5
100	41.8	41.7	41.9	40.2	41.8	41.8	41.8	41.0	41.9	41.7	41.9	41.8
140	42.4	40.8	41.9	39.9	41.2	41.1	41.3	41.2	41.7	40.9	41.6	41.0
140	42.3	41.5	41.3	39.7	41.1	40.7	41.7	39.9	41.8	41.8	43.0	42.4
140	40.3	41.5	40.4	41.8	42.1	40.9	41.3	41.8	41.4	41.4	42.0	41.5
140	42.4	42.4	40.6	42.7	42.3	42.1	41.8	42.0	42.0	41.0	42.7	42.7
180	40.1	40.8	41.1	41.9	40.9	41.4	41.3	*	41.1	41.6	40.9	41.5
180	42.5	41.7	38.3	42.8	42.3	41.4	41.8	40.8	42.2	40.9	41.7	41.0
180	42.1	40.7	43.0	40.1	41.9	39.6	41.7	40.9	42.2	40.5	42.0	39.5
180	41.9	41.5	42.3	43.1	42.6	42.0	43.2	41.6	42.8	41.1	43.0	41.8
180	41.1	41.7	42.0	41.6	41.5	39.7	40.8	42.1	41.7	*	41.8	41.4
180	41.7	40.5	42.4	40.8	41.5	41.7	42.2	41.8	42.1	41.8	41.4	41.1
180	40.1	41.7	41.0	41.3	41.3	41.4	41.7	41.8	40.7	41.7	41.2	*

* Data missing.

Table IV.  Disease free survival (DFS) and overall survival (OS).

CDDP dose (mg m^−2)	Pathologic CR # pts/OS (months)	Clinical CR # pts/OS (months)	Clinical PR # pts/OS (months)	Clinical NR # pts/OS (months)
Disease free survival
60	0	1/12
100	1/27	1/27
140	1/14	2/14
		24
180	2/1	7/1
18	5
		10
		11
		13
		18
		34
Overall survival
60		1/33	1/34	1/14
100	1/71	1/71	2/26	4/2
			39	7
				26
				62
140	1/96	2/96+	2/13	4/3
		107+	28	8
				13
				42
180	2/23	7/14	2/30	9/3
78	23	37	3
		32		5
		57		10
		62+		10
		67+		34
		78		35
				58
				75+